This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The outcomes estimated from the literature were: the prevalence of disease, disease progression and regression, the cancer treatment probabilities, the diagnostic inaccuracy rates, and the health state utilities.
Study designs and other criteria for inclusion in the review
The authors did not state whether a systematic review of the literature was undertaken to identify the primary studies. It was only stated that data on screening efficacy in preventing mortality due to cancer were taken from retrospective studies.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Forty-seven studies were used as the primary sources of clinical data.
Methods of combining primary studies
A narrative approach appears to have been used to combine the primary estimates.
Investigation of differences between primary studies
Results of the review
The prevalence of BE in GERD was 0.1, the prevalence of LGD in GERD was 0.01, the prevalence of HGD in GERD was 0.007, and the prevalence of cancer in BE was 0.067. The annual regression probabilities were 0.0175 from BE to normal, 0.63 from LGD to no dysplasia, 0.1 from HGD to no dysplasia, and 0.07 from HGD to LGD.
In terms of the cancer treatment probabilities:
the rate of resectability was 0.5 without surveillance and 0.95 with surveillance; the surgical mortality was 0.05 without surveillance and 0.027 with surveillance; the cancer cure rate was 0.2 without surveillance and 0.8 with surveillance; and mortality from endoscopy was 0.000021.
Mortality from all other causes was age-and gender-dependent.
In terms of the diagnostic inaccuracy, the probabilities of diagnosis were: The utility values were 1 (range: 0.90 to 1) for GERD and 0.97 (range: 0.83 to 1) for post-oesophagectomy.
Methods used to derive estimates of effectiveness
The sensitivity analysis showed that decrements in the utility associated with diagnosing BE could be as high as 9% at a WTP of $50,000, and as high as 10.5% at a WTP of $100,000, and that screening would remain cost-effective. Similar conclusions were reached when changes in other utility values were considered. In the worst case for screening, the threshold was never lower than 5%, which still represents a relatively high value.
Authors' conclusions
Screening with surveillance of Barrett's oesophagus (BE) was cost-effective in comparison with no screening, regardless of any possible decrements in utility caused by diagnosing BE.
CRD COMMENTARY -Selection of comparators
The rationale for the choice of the comparator (no screening) was appropriate as this represented the standard alternative to the intervention examined in the study. You should decide whether this is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness evidence came from published studies. The authors did not explicitly state whether a systematic review of the literature was undertaken, so it is possible that the primary studies might have been identified selectively. In addition, there was limited information on the design and other characteristics of the primary studies. Thus, the validity of the primary sources could not be assessed. The authors stated that most studies were retrospective, and these usually have a low internal validity. No information on the approach used to extract and combine the primary estimates was provided, and the issue of heterogeneity across the primary studies was not addressed. The robustness of the study conclusions to variations in clinical estimates was investigated in the sensitivity analysis. The use of experts' opinions that were not supported by published data introduced further uncertainty in the clinical analysis.
Validity of estimate of measure of benefit
QALYs are an appropriate benefit measure because they capture the impact of the intervention on both quality of life and survival, which are relevant dimensions of health for patients with cancer. The analysis focused on QOL aspects and most data on QOL were based on authors' consensus. Some utility weights were estimated from studies that used the time trade-off approach. The use of QALYs permits comparisons to be made with the benefits of other health care interventions. Discounting was applied.
Validity of estimate of costs
The costs included were consistent with the perspective considered in the analysis. A detailed breakdown of the cost items was not given, and neither was information on the unit costs and quantities of resources used. This limits the possibility of replicating the analysis in other settings. The cost estimates were specific to the study setting and were not varied in the sensitivity analyses. The impact of using alternative sources of the costs was not investigated. Moreover, no statistical analyses were carried out. The price year was implicitly reported, which will facilitate reflation exercises in other time periods. Few details of resource consumption were provided. Discounting was relevant and was appropriately carried out.
